Gaviscon 250mg + 133.5mg Mint Taste 24 Chewable Tablets

Gaviscon 250mg + 133.5mg Mint flavor

Symptomatic treatment of occasional heartburn

Dosage

Chewable tablets (strawberry flavor and mint flavor) Adults and adolescents (12–18 years): 1–2 tablets of 500 mg + 267 mg after meals and at bedtime. 2–4 tablets of 250 mg + 133.5 mg after meals and at bedtime. For oral administration. The tablets should be chewed well (they can be broken up and chewed a little at a time). Afterwards you can drink some water. Oral suspension Adults and adolescents (12–18 years): 10–20 ml (second – fourth notch of the measuring cup or 2–4 measuring spoons or 1– 2 single-dose sachets) after meals and at bedtime. For oral administration. Shake the suspension before use. Special populations Elderly: there is no need to adjust the doses for this age group. Patients with renal insufficiency : The reduced ability to urinate the exogenous salt supplement provided by antacids can affect potentially severe electrolyte imbalances (see section 4.4).

Active principles

Gaviscon 500 mg + 267 mg chewable tablets mint flavor One tablet contains: Active ingredients: sodium alginate 500 mg sodium bicarbonate 267 mg Excipients: aspartame 7.5 mg Gaviscon 250 mg + 133.5 mg chewable tablets mint flavor One tablet contains: Active ingredients : sodium alginate 250 mg sodium bicarbonate 133.5 mg Excipients: aspartame 3.75 mg Gaviscon 250 mg + 133.5 mg chewable tablets strawberry flavor One tablet contains: Active ingredients: sodium alginate 250 mg sodium bicarbonate 133.5 mg Excipients: aspartame 8, 80 mg Gaviscon 500mg / 10ml + 267mg / 10ml oral suspension 10ml contain: Active ingredients: sodium alginate 500 mg sodium bicarbonate 267 mg Excipients: methyl parahydroxybenzoate 40 mg propyl parahydroxybenzoate 6 mg Gaviscon 500mg / 10ml + 267mg / 10ml oral suspension mint flavor 10 ml contain: Active ingredients: sodium alginate 500 mg sodium bicarbonate 267 mg Excipients: methyl parahydroxybenzoate 40 mg propyl parahydroxybenzoate 6 mg For the complete list of excipients, see section 6.1.

Excipients

Chewable tablets with mint flavor Mannitol (E421); calcium carbonate; magnesium stearate; copovidone; aspartame (E951); acesulfame potassium (E950); macrogol 20,000; mint flavor. Strawberry flavored chewable tablets Xylitol, mannitol, calcium carbonate; macrogol 20,000, strawberry flavor, aspartame, magnesium stearate; red iron oxide. Oral suspension Calcium carbonate; carbomers; methyl parahydroxybenzoate; propyl parahydroxybenzoate; sodium saccharin; fennel flavoring; sodium hydroxide; erythrosine; purified water. Mint flavored oral suspension Calcium carbonate; carbomers; methyl parahydroxybenzoate; propyl parahydroxybenzoate; sodium saccharin; mint flavor; sodium hydroxide; purified water.

Contraindications

Hypersensitivity to the active substances or to any of the excipients, including ester of hydroxybenzoates (parabens). Severe renal insufficiency.

Warnings

Do not use for prolonged treatments. In patients with very low gastric acid levels there is a possibility of lower efficacy. In adolescents (12–18 years) use only when clearly needed and under close medical supervision. In case of renal insufficiency, the medicinal product should be used with caution as the exogenous salt supplement provided by antacids can affect potentially severe electrolyte imbalances. Each 500 mg + 267 mg tablet contains 123 mg (5.3 mmol) of sodium. Each 250 mg +133.5 mg tablet contains 61.5 mg (2.65 mmol) of sodium. Each 10 ml dose of suspension contains 141 mg (6.2 mmol) of sodium. This should be taken into consideration in cases where a particularly low-salt diet is recommended, for example in some cases of congestive heart failure and renal impairment. Each 500 mg + 267 mg tablet contains 160 mg (1.6 mmol) of calcium carbonate. Each 250 mg +133.5 mg tablet contains 80 mg (0.8 mmol) of calcium carbonate. Each 10 ml dose of suspension contains 160 mg (1.6 mmol) of calcium carbonate. Care should be taken when treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium-containing kidney stones. The tablets contain aspartame, a source of phenylalanine and should therefore not be taken by patients with phenylketonuria. The suspension contains methyl parahydroxybenzoate and propyl parahydroxybenzoate which may cause allergic reactions. Delayed-type reactions (contact dermatitis) usually occur, rarely immediate reactions with urticaria and bronchospasm.

Pregnancy

Use in case of real need and under strict medical supervision.

Side effects

Below are the side effects of Gaviscon, organized according to the MedDRA system organ class. They are divided by frequency (very common (≥ 1/10), common (≥ 1/100 to ≤ 1/10), uncommon (≥ 1 / 1,000 to ≤ 1/100), rare (≥ 1 / 10,000 to 1 /1,000), very rare (≤ 1 / 10,000)). Gastrointestinal disorders Very rare: flatulence, nausea Skin and subcutaneous tissue disorders Very rare: fluid retention (edema). Immune system disorders Very rare: allergic manifestations such as urticaria and bronchospasm, anaphylactic or anaphylactoid reactions. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.

Overdose

Experience with overdose is very limited. The only possible consequence of overdose is abdominal distension: in this case, resort to symptomatic treatment by adopting generic support measures.

Interactions

It is advisable to interpose an interval of at least two hours between taking Gaviscon and that of other drugs.

storage

Oral suspension and mint flavored oral suspension: do not store above 30 ° C. Store in the original package. Do not refrigerate. Mint flavored oral suspension in sachets: do not store above 25 ° C. Store in the original package. Do not refrigerate. Mint-flavored chewable tablets: do not store above 30 ° C. Store in the original package. Strawberry flavored chewable tablets: do not store above 25 ° C. Store in the original package.

Format

Pack of 24 chewable tablets with mint flavor
(250 mg + 133.5 mg)

Discover the Gaviscon world!